statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights REGENXBIO to Host Conference Call on August 1 to Discuss Second...

REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger...

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II REGENXBIO Announces Successful Pre-BLA Meeting with FDA to...

REGENXBIO Announces Leadership Transition

REGENXBIO Announces Leadership Transition REGENXBIO Announces Leadership Transition PR Newswire ROCKVILLE, Md., June 12, 2024 Curran Simpson, Chief Operating Officer, Appointed as President and...

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

 Latest Ratings for RGNX
 DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB...

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire ROCKVILLE...

Evaluating Regenxbio: Insights From 9 Financial Analysts

Latest Ratings for RGNX
 DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsMarket Perform Feb 2022SVB LeerinkMaintainsMarket Perform Jan 2022SVB LeerinkMaintainsMarket Perform
 View More Analyst...

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., May 10, 2024 ROCKVILLE, Md., May 10, 2024 /PRNewswire...

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights PR Newswire...

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Volume	318,487.00
52-Wk High	$28.80
52-Wk Low	$10.49

RGNX Regenxbio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals